Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in HFrEF Patients With Severe Tricuspid Regurgitation and Right Heart Failure
KCT0012087Phase 4Not yet recruiting
- Sponsor
- The Joongbu Society of Cardiology
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vericiguat in heart failure with reduced ejection fraction (HFrEF), Tricuspid insufficiency (TR) and Right heart dysfunction (RHF), sponsored by The Joongbu Society of Cardiology. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)Tricuspid insufficiency (TR)Right heart dysfunction (RHF)
Beyond the preview
Go deeper on KCT0012087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012087.